Formerly dba ViroLogic, Inc. and having acquired Aclara Bioscisnces in 2004 - also SBIR involved - in 2009 Monogram Biosciences, Inc (NASDAQ: MGRM) - IPO in May 2000 - was itself acquired by by LabCorp, Monogram had been in the business of developing and commercializing diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. The firm had offered HIV tests, including genotypic, phenotypic, tropism, and combined phenotype/genotype assays, as well as suppression management and viral load testing; HCV assays; and oncology tests. Monogram also provided biopharmaceutical partners and research collaborators with clinical, scientific, and logistical support for critical drug development projects in HIV infection, HCV infection, and oncology via agreements, strategic alliances, and long term partnerships. Founded in 1995 and very active in the SBIR space both diredtly and by collaborating with other SBIR involved firms, Monogram was headquartered in South San Francisco, CA. As of August 2009, Monogram Biosciences, Inc. operates as a subsidiary of Laboratory Corp. of America Holdings.
